Scaling from Clinical Development to Commercial Production 

Clinical development is where a therapy proves its value, but commercial production is where that value has to hold up at scale.  

By the time a drug, biologic, or medical product is moving toward launch, life sciences companies should have a manufacturing process that can consistently produce quality product, a regulatory strategy that supports approval, and a team that can move quickly without creating avoidable compliance risk. 

That transition is becoming more demanding as the development landscape grows more active. ClinicalTrials.gov reported 595,847 registered studies as of July 27, 2026, including 65,451 recruiting studies across global locations.  

Advancing through clinical phases is a challenge in itself. But the bigger operational test is building a reliable bridge between clinical development, tech transfer, manufacturing readiness, regulatory submission, quality systems, and commercial supply. 

Why the Clinical-to-Commercial Handoff Matters 

A therapy can perform well in clinical trials and still face serious launch barriers if manufacturing, quality, and supply planning are not ready.  

The clinical-to-commercial handoff brings together groups that often operate on different timelines—R&D, clinical operations, regulatory affairs, quality, manufacturing, supply chain, validation, data, and commercial teams. 

That handoff matters because regulators expect manufacturing processes to be controlled, documented, and repeatable—also known as process validation. The FDA’s Process Validation Guidance defines process validation as the “collection and evaluation of data, from the process design stage through commercial production,” to establish scientific evidence that a process can consistently deliver quality product.  

This shows that early development decisions are tied directly to commercial production. Process knowledge should not stay locked inside early development teams. It needs to carry into tech transfer, process qualification, continued monitoring, and long-term quality management. 

Common Bottlenecks When Scaling to Commercial Production 

Even well-run life sciences organizations can run into delays during scale-up. The most common issues tend to come from misalignment, under-planning, or resource gaps. 

Common bottlenecks include: 

• Late manufacturing involvement during clinical development 
• Incomplete process knowledge transfer between teams or sites 
• Validation timelines that do not match launch expectations 
• Supplier qualification delays 
• Quality documentation gaps 
• Limited availability of specialized GxP talent 
• Siloed systems across clinical, quality, and manufacturing 
• Inspection readiness work that starts too late 
• Commercial demand forecasts that are not tied to production capacity 

Most of these issues are preventable. They require earlier planning, clearer ownership, and the right mix of internal and external support. 

How to Scale from Clinical Development to Commercial Production 

When it comes to scaling from clinical development to commercial production, there are a few key elements that should be top of mind from the very beginning of the process. 

Start Commercial Planning Prior to Launch 

Commercial production should not be treated as a final-phase activity. The earlier manufacturing teams are involved, the easier it becomes to identify process risks, facility needs, analytical requirements, supplier gaps, and workforce constraints before they slow down launch. 

This is especially true for products with complex manufacturing requirements, such as biologics, sterile injectables, cell and gene therapies, or products that require cold chain coordination. 

Clinical batches may show that a product can be made under controlled conditions, while commercial production has to show that the product can be made repeatedly at the scale patients and providers need. 

Early planning should focus on practical questions such as: 

• Can the process scale without weakening quality controls? 
• Are raw materials and suppliers qualified for commercial demand? 
• Are analytical methods ready for validation and routine use? 
• Does the facility have the right equipment, capacity, and contamination controls? 
• Are batch records, deviations, and process risks documented clearly? 
• Do quality, regulatory, and manufacturing teams agree on readiness? 
• Is the workforce prepared for validation, inspection, and launch activity? 

These questions are easier to answer when clinical development and manufacturing teams work together before the trial phase ends. Waiting until the submission window can leave companies trying to solve process, people, and compliance issues at the same time. 

Build Tech Transfer Around Process Knowledge 

Tech transfer is one of the most important steps between clinical development and commercial production. It’s also one of the easiest places for details to get lost. 

A strong tech transfer process should include batch records, analytical methods, critical process parameters, critical quality attributes, equipment requirements, supplier information, deviation history, and lessons learned during clinical manufacturing. 

Commercial teams also need context around prior process changes, known sensitivities, and unresolved risks. Manufacturing teams need enough process understanding to troubleshoot effectively, support inspections, manage deviations, and maintain quality as production demand grows. 

The Process Validation Guidance reinforces this lifecycle view by connecting process design, qualification, and continued verification. Validation should be a series of activities across the product and process lifecycle, rather than a one-time check before launch.  

Make Quality Systems Part of the Scale-Up Strategy 

Quality systems influence how quickly a company can move from approval readiness to commercial reliability.  

Documentation, deviation management, CAPA processes, supplier qualification, change control, training, and inspection readiness all affect whether production can scale without creating avoidable risk. 

Manufacturing quality remains closely linked to product availability, which helps explain why quality maturity matters long before commercial launch. Weak documentation or unclear ownership can slow validation, complicate inspection readiness, and make production issues harder to resolve. 

A stronger scale-up strategy should include: 

• Clear ownership for quality decisions during tech transfer 
• Early readiness assessments for validation and inspection activity 
• Training plans for operators, quality teams, and technical staff 
• Deviation and CAPA processes that can support commercial volume 
• Supplier risk reviews before demand increases 
• Documentation practices that support regulatory review and routine production 

Quality teams should not be brought in only to review final materials. Quality needs a practical role in shaping how the process is transferred, controlled, monitored, and improved. 

Plan for Regulatory Readiness Before Submission 

Chemistry, manufacturing, and controls information, validation documentation, labeling, inspection readiness, facility preparedness, and quality systems all affect how prepared a company is for review and launch. 

This is especially relevant as FDA review pathways continue to evolve. The Commissioner’s National Priority Voucher (CNPV) program was launched to reduce review times for certain product applications. The pilot targets a 1- to 2-month review timeline for selected applications, compared with 6 or more months under other priority review programs.  

Not every product qualifies for this type of pathway, and speed doesn’t remove the need for strong evidence. Applications in the CNPV pilot remain subject to the same statutory and regulatory approval requirements as applications outside the program.  

Faster review pathways only create value when internal teams are prepared. Regulatory, quality, manufacturing, and clinical teams need complete documentation, clear handoffs, and aligned ownership before timelines become compressed. 

Align Manufacturing Capacity with Commercial Demand 

Demand forecasting, launch sequencing, inventory planning, supplier availability, packaging needs, labeling requirements, and market access timing can all affect production decisions. 

Supply chain resilience needs to be designed early. If a company depends on limited suppliers, constrained manufacturing sites, or specialized materials, commercial production can become vulnerable even after approval. 

Companies can strengthen capacity planning by evaluating: 

• Whether internal or external manufacturing is the right fit 
• Where redundant suppliers are needed 
• How long lead times affect launch inventory 
• Which markets require different packaging, labeling, or regulatory steps 
• Whether commercial demand may outpace validated capacity 
• How quality events could affect supply continuity 

Capacity planning should help companies avoid reaching approval with a production model that can’t support the launch. 

Build the Right Workforce for Scale 

Clinical development and commercial production require different workforce models. During development, companies may rely heavily on clinical operations, data management, regulatory strategy, biostatistics, and medical writing. As products move closer to commercialization, the talent mix widens. 

Commercial production may require validation engineers, quality assurance specialists, manufacturing associates, automation experts, supply chain planners, CSV specialists, regulatory CMC support, project managers, and inspection readiness teams.  

This is where many companies can start to feel pressure. Internal teams are often already stretched by ongoing trials, submission work, tech transfer, and launch planning. Hiring permanent teams for every surge may not make sense, but under-resourcing critical functions can slow down the path to market. 

A flexible workforce strategy can help companies scale around demand. That may include project-based teams, functional service provider support, contract talent, managed delivery teams, or targeted consulting support for quality, validation, regulatory, and manufacturing. 

Use Data and Digital Tools to Reduce Launch Friction 

Data visibility can make the clinical-to-commercial transition smoother. When teams rely on disconnected systems, manual reporting, or siloed documents, it becomes harder to identify risks before they affect timelines. 

Digital tools can help teams track process knowledge, batch performance, validation status, supplier risk, quality events, and launch milestones in a more connected way. The goal should be better operational visibility, not more reporting for teams that are already under pressure. 

In regulated environments, digital modernization also has to be practical. Systems need to support GxP expectations, data integrity, audit trails, controlled access, and validation requirements. 

Get Support for the Clinical-to-Commercial Transition 

Moving from clinical development to commercial production is one of the most important transitions in the life sciences lifecycle. Life sciences companies need manufacturing processes, quality systems, suppliers, documentation, and teams toexecute under pressure. 

Insight Global can help life sciences organizations move through that transition with confidence. As a functional service provider, we support the talent, technical, regulatory, quality, manufacturing, and transformation needs that come with scaling from development to commercialization. 

Contact us to learn more.